Histopathologically confirmed EGFR mutation-positive stage Ia non-small cell lung cancer (NSCLC) with high-risk factors
Conditions
Interventions
Three-generation EGFR-TKI adjuvant therapy for Chinese patients with stage IA EGFR-positive NSCLC who have high-risk factors:NA
Sponsors
The First Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age = 18 years old; 2. Patients with IA-stage (8th edition of AJCC staging) non-small cell lung cancer (NSCLC) confirmed by histopathology and with high-risk factors; 3. EGFR mutation positive; 4. No previous systemic anti-tumor treatment; 5. Expected or already received surgical treatment; 6. Intended to receive or already received third-generation EGFR-TKI adjuvant therapy after surgery.
Exclusion criteria
Exclusion criteria: 1. Small cell lung cancer; 2. With other malignant tumors that require treatment; 3. Pregnant or lactating women; 4. Those who the researchers consider not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-Years Disease-Free Survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 5-Years Disease-Free Survival rate;Disease-free survival(DFS);5 years Overall Survival;3-years Overall Survival;Overall Survival;The type, frequency and severity of adverse events during treatment (TEAE) and treatment-related adverse events (TRAE); | — |
Countries
China
Contacts
Public ContactYang Nuo
The First Affiliated Hospital of Guangxi Medical University
Outcome results
None listed